Last reviewed · How we verify
NCT05986552: IST-IGST
The Influence of Treatment Format on Schema Therapy for Borderline Personality Disorder
NA trial testing Individual Schema Therapy (IST) in Borderline Personality Disorder in 132 participants. Enrolling by invitation.
1 March 2027
Quick facts
| Lead sponsor | University of Amsterdam |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 132 |
| Start date | 10 November 2023 |
| Primary completion | 1 March 2027 |
| Estimated completion | 30 December 2027 |
| Sites | 2 locations across Netherlands |
Drugs / interventions tested
- Individual Schema Therapy (IST)
- Individual-Group Schema Therapy (IGST)
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
Sponsor
University of Amsterdam
Who can join
Adults 18 to 70, any sex, with Borderline Personality Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to compare etc. in patients with borderline personality disorder pure individual schema therapy to combined individual-group schema therapy. The main questions it aims to answer are: * is there a difference in effectiveness? * is there a difference in (early) treatment dropout? Participants will receive either * individual schema therapy or * combined individual-group schema therapy. Researchers will compare individual to combined individual-group schema therapy see if there is a difference in effects and/or a difference in dropout from treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05986552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT07119541 — Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder · NA · active not recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
Other University of Amsterdam trials
Trials by the same sponsor.
- NCT07505238 — Informing Patients About Their Surgery's Environmental Impact: an Effective Pathway to Sustainable Healthcare? · NA · not yet recruiting
- NCT07362511 — Imagery Rescripting in Primary Care · NA · recruiting
- NCT06966323 — Hold me Tight/Let me Go: Effectiveness of a Course to Enhance Parent-adolescent Relationship · recruiting
- NCT06336551 — Acceptance and Commitment Therapy for Insomnia · NA · completed
- NCT05976945 — Imagery Rescripting as Treatment for Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05986552 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Amsterdam
- Last refreshed: 20 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05986552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing